The stock's fall snapped a two-day winning streak.

Shareholders might have noticed that Cencora, Inc. (NYSE:COR) filed its quarterly result this time last week. The early response was not positive, with shares down 3.1% to US$283 in the past week.

In its first-quarter 2025 investor letter, TimesSquare Capital U.S. Focus Growth Strategy highlighted stocks such as Cencora, Inc. (NYSE:COR). Cencora, Inc. (NYSE:COR) is a pharmaceutical products ...

Shares of Cencora Inc. COR shed 6.83% to $283.77 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.58% to 5,663.94 ...

Hello, everyone, and thank you for joining the Cencora Fiscal 2025 Second Quarter Results Conference Call. My name is Lucy, and I will be coordinating your call today. [Operator Instructions] I ...

LONDON - Cencora, Inc., a company whose securities are listed on the New York Stock Exchange, has concluded a post-stabilisation period without any stabilisation activities being conducted ...

CONSHOHOCKEN, Pa. (AP) — CONSHOHOCKEN, Pa. (AP) — Cencora, Inc. (COR) on Wednesday reported fiscal second-quarter profit of $717.9 million. On a per-share basis, the Conshohocken, Pennsylvania ...

Shares of Cencora (COR) have been strong performers ... One industry peer that looks good is Pediatrix Medical Group, Inc. (MD). MD has a Zacks Rank of # 2 (Buy) and a Value Score of A, a Growth ...